Switching from Tirzepatide to Semaglutide: A Microdosing Perspective
Switching between GLP-1s on a microdose schedule is gentler than the weekly equivalent. Smaller daily doses give your body time to adapt at each step, and the lower peak concentrations reduce the side-effect spike that often hits during transitions. Microdose-to-microdose conversions can usually be done overnight; weekly-to-microdose transitions need a 1-2 week wash-down period. The conversion ratios below apply, with adjustments noted for split protocols.
Important Disclaimer
This article is for research purposes only. Any medication changes should be discussed with your healthcare provider. The information provided is based on available research data and should not be used for medical decision-making.
Overview
Switching from Tirzepatide (Mounjaro/Zepbound) to Semaglutide (Ozempic/Wegovy) involves transitioning from a dual agonist (GLP-1/GIP) to a single GLP-1 receptor agonist. This guide covers the benefits, risks, and considerations for making this switch.
Potential Benefits
- FDA-approved for both diabetes and weight loss
- Extensive clinical experience
- Well-established safety profile
- Once-weekly dosing
- Proven efficacy for weight loss
Potential Drawbacks
- Loss of GIP activity
- Need to restart titration
- Different side effect profile
- Potential for reduced efficacy
- May require dose adjustment
Dose Conversion
When switching from Tirzepatide to Semaglutide, it's important to follow proper dose conversion guidelines. Use our calculator to determine the appropriate starting dose:
GLP-1 Dose Conversion CalculatorSide Effects During Transition
When switching medications, you may experience:
- Gastrointestinal symptoms
- Changes in appetite
- Blood sugar fluctuations
- Energy level changes
- Potential metabolic changes